Atrial natriuretic peptide and catecholamines in obstructive sleep apnea syndrome

A. Baruzzi, R. Riva, F. Cirignotta, M. Zucconi, M. Cappelli, E. Lugaresi

Research output: Contribution to journalArticlepeer-review


Noctural polyuria with repeated micturitions during the night is a clinically evident feature of obstructive sleep apnea syndrome (OSAS). These effects are reversed by continuous positive airway pressure (CPAP). There is some evidence that atrial natriuretic peptide (ANP) and catecholaminergic activity may be implicated in the pathogenesis of these symptoms. We studied these biochemical parameters in six patients with severe OSAS during two nights: the first (basal) in their normal conditions and the second during CPAP treatment. CPAP treatment reversed apnea episodes in all our patients. A significant (p <0.035) reduction of nocturnal urine volume (from 902 ± 297 to 447 ± 130 ml; mean ± SD), sodium excretion (from 150 ± 33 to 89 ± 35 mEq/12h), noradrenaline excretion (from 95 ± 101 to 52 ± 16 μg/g creatinine), noradrenaline plasma concentrations (from 325 ± 96 to 259 ± 75 pg/ml), ANP plasma concentrations (from 35 ± 20 to 19 ± 5 pg/ml) was observed during the night under CPAP application. These data suggest that in OSAS patients the high ANP plasma concentration is responsible for the observed elevated diuresis and sodium excretion. These effects are rapidly reversible, as they are reversed during the first CPAP treated night.

Original languageEnglish
Pages (from-to)83-86
Number of pages4
Issue number1
Publication statusPublished - 1991


  • Atrial natriuretic factor
  • Catecholamines
  • Continuous positive airway pressure
  • Sleep apnea

ASJC Scopus subject areas

  • Physiology


Dive into the research topics of 'Atrial natriuretic peptide and catecholamines in obstructive sleep apnea syndrome'. Together they form a unique fingerprint.

Cite this